Ageless Pep Academy Clinical Education Β· Licensed Prescribers

Semaglutide

Semaglutide

⚠️ Structural Separation Notice

The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.

GLP-1 receptor agonist with extended half-life via C-18 fatty di-acid albumin binding; FDA-approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and oral T2D (Rybelsus).

Quick Facts

Property Value
Also Known As Ozempic (T2D, SubQ), Wegovy (obesity, SubQ), Rybelsus (oral T2D)
Category Metabolic / Weight Loss
Sequence Modified GLP-1(7-37) analog; Aib8 substitution, C-18 fatty di-acid acylated at Lys26 via mini-PEG linker
Molecular Weight ~4113.6 Da
Molecular Formula C187H291N45O59
PubChem CID 56843331
Administration SubQ (weekly) / Oral (daily)
Typical Dose Range SubQ: 0.25-2.4 mg weekly (titrated); Oral: 3-14 mg daily (T2D), 50 mg daily (OASIS obesity)
Half-Life ~1 week (165 hours) β€” albumin binding extends duration
Storage Pre-filled pen: 2-8C refrigerated, room temp up to 56 days after first use. Compounded lyophilized: -20C; reconstituted 2-8C for 28 days
FDA Status APPROVED β€” Ozempic (T2D, Dec 2017), Wegovy (chronic weight management, June 2021), Rybelsus (oral T2D, Sept 2019)
WADA Status Not prohibited (FDA-approved prescription medication)

Mechanism of Action

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor (GLP1R, UniProt P43220) agonist with 94% amino acid homology to native human GLP-1. Its key structural modification β€” a C-18 fatty di-acid chain conjugated at Lys26 via a mini-PEG linker β€” confers high-affinity albumin binding in the circulation, shielding the molecule from dipeptidyl peptidase-4 (DPP-4) degradation and extending the half-life to approximately 165 hours (enabling once-weekly subcutaneous dosing). An Aib8 substitution at position 8 further enhances DPP-4 resistance (PMID 33320179).

Upon binding the GLP-1 receptor, semaglutide activates the adenylyl cyclase/cAMP/PKA signaling cascade. In pancreatic beta cells, this potentiates glucose-dependent insulin secretion while simultaneously suppressing glucagon release from alpha cells β€” a dual mechanism that improves glycemic control with minimal hypoglycemia risk. Peripherally, GLP-1R activation delays gastric emptying, prolonging nutrient transit time and contributing to post-prandial satiety.

The weight loss effects of semaglutide are primarily mediated through central nervous system GLP-1R signaling. In the hypothalamus, semaglutide activates POMC/CART anorexigenic neurons and suppresses NPY/AgRP orexigenic pathways, producing robust appetite reduction. Emerging evidence also demonstrates modulation of mesolimbic dopaminergic reward circuits, reducing hedonic food intake and food craving behavior. These central mechanisms account for the magnitude of weight loss (approximately 15-17% body weight at the 2.4 mg dose), which substantially exceeds what gastric emptying delay alone could produce (PMID 33320179).

Semaglutide also exerts cardiovascular protective effects through anti-inflammatory actions, improved endothelial function, and potentially direct cardiac GLP-1R-mediated effects. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in individuals with obesity and established cardiovascular disease, independent of diabetes status (PMID 37952131).

Key Research Areas

  1. Chronic weight management β€” The STEP clinical trial program (STEP 1-5, 8) established semaglutide 2.4 mg weekly as the most effective single-agent anti-obesity medication approved to date, with mean weight loss of 14.9-17.4% across trials (PMID 33567185, PMID 33667417, PMID 33625476, PMID 36216945).
  2. Type 2 diabetes β€” The SUSTAIN program demonstrated superior HbA1c reduction versus comparators including other GLP-1RAs, with cardiovascular safety confirmed in SUSTAIN 6 (PMID 27633186).
  3. Cardiovascular risk reduction β€” SELECT trial: 20% reduction in MACE (cardiovascular death, nonfatal MI, nonfatal stroke) in patients with overweight/obesity and CVD but without diabetes (PMID 37952131). SOUL trial extended CV benefit to oral semaglutide (14 mg daily) in T2D + established ASCVD/CKD: 14% MACE reduction, HR 0.86 (95% CI 0.77-0.96), n=9,650 (PMID 40162642) β€” the first CV outcomes trial confirming benefit for an oral GLP-1 agent.
  4. Adolescent obesity β€” STEP TEENS demonstrated safety and efficacy in adolescents aged 12 to <18, with -16.1% mean BMI change at 68 weeks (vs +0.6% placebo) in n=201 participants; ~73% achieved β‰₯5% body weight reduction vs ~18% placebo. Safety profile consistent with adult STEP program; no new pediatric-specific signals (PMID 36322838, Weghuber D et al., NEJM 2022;387(24):2245-2257, NCT04102189). Led to FDA expanded approval of Wegovy for adolescents β‰₯12 years.
  5. Oral formulation β€” Rybelsus (oral semaglutide with SNAC absorption enhancer) approved for T2D; OASIS 1 trial demonstrated efficacy of oral semaglutide 50 mg daily for obesity (PMID 37385278). SOUL adds cardiovascular outcome evidence for the 14 mg oral T2D dose (PMID 40162642). Higher-dose oral expansion β€” PIONEER PLUS (PMID 37385279, Aroda VR et al., Lancet 2023;402(10403):693-704) demonstrated that oral sem 25 mg and 50 mg are superior to 14 mg in T2D (HbA1c βˆ’1.9/βˆ’2.2 vs βˆ’1.5 pp; weight βˆ’7.0/βˆ’9.2 vs βˆ’4.5 kg at wk 52). OASIS 4 (PMID 40934115, Wharton S et al., NEJM 2025;393:1077-1087, NCT05564117) established oral sem 25 mg for obesity without T2D (βˆ’13.6% treatment-policy / βˆ’16.6% adherent weight loss at 64 wk) β€” supporting the FDA approval of oral Wegovy (August 2025). Oral semaglutide is now a credible alternative for injection-averse patients, though pharmacokinetics and dosing requirements (fast, ≀120 mL water, 30-min delay before next food) differ from injectable.
  6. Obesity comorbidities β€” Demonstrated benefits for knee osteoarthritis symptoms, NAFLD/MASH, and obstructive sleep apnea in dedicated trials (PMID 39476339).
  7. Peripheral artery disease functional benefit β€” STRIDE (Phase 3b, n=792): first trial demonstrating improved maximum walking distance, pain-free walking distance, and health-related quality-of-life in patients with T2D + symptomatic PAD (Fontaine IIa) on semaglutide 1.0 mg weekly vs placebo (PMID 40169145). Establishes new evidence-based indication territory beyond MACE/kidney/weight endpoints.

Evidence Level Summary

Evidence Type Count Notes
Human RCTs 12+ STEP 1-5, 8; STEP UP (7.2 mg); SUSTAIN 1-6; SELECT; OASIS 1; FLOW; STEP TEENS β€” largest RCT program for any anti-obesity medication
Human observational 1+ Real-world effectiveness data confirming trial findings
Systematic reviews / Meta-analyses 2+ GI safety meta-analysis; efficacy meta-analysis across weight loss trials
Narrative reviews 1+ Mechanism and pharmacology reviews
Animal in vivo Multiple Preclinical GLP-1R signaling and CNS mechanism studies

This represents the strongest evidence base of any peptide in the vault. Semaglutide has Phase III data across multiple indications, three FDA approvals, and a landmark cardiovascular outcomes trial.

Clinical Applications

  • Weight Management β€” 14.9-17.4% mean body weight loss at 2.4 mg/week (STEP program); ~20.7% at 7.2 mg (STEP UP)
  • Fat Loss β€” Preferential reduction in visceral adiposity; improved waist circumference
  • Type 2 Diabetes β€” HbA1c reductions of 1.0-1.8% with concurrent weight loss (SUSTAIN program)
  • Metabolic Syndrome β€” Improvements across multiple cardiometabolic parameters (blood pressure, lipids, inflammatory markers)
  • Peripheral artery disease (PAD) with T2D β€” STRIDE demonstrated walking capacity and quality-of-life improvement in Fontaine stage IIa PAD on 1.0 mg weekly (PMID 40169145)
  • Cardiovascular outcomes (oral) β€” SOUL demonstrated 14% MACE reduction in T2D + ASCVD/CKD on oral semaglutide 14 mg (PMID 40162642)
  • Heart failure with preserved ejection fraction (HFpEF) + obesity β€” STEP-HFpEF and STEP-HFpEF DM trials, plus the 4-trial pooled HF analysis, establish semaglutide as disease-modifying in the obesity-HFpEF phenotype. In the 4-trial pool across SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM (n=3,743 with HF), HR 0.69 (95% CI 0.53-0.89) for cardiovascular death or worsening HF events (PMID 39222642). STEP-HFpEF (non-T2D, n=529: PMID 37622681) and STEP-HFpEF DM (T2D, n=616: PMID 38587233) both demonstrated KCCQ-CSS gains of 7-8 points, 6-minute walk improvement, body weight reduction of 9-13%, and CRP reduction. Pooled STEP-HFpEF (n=1,145: PMID 38599221) and SELECT HF subgroup (n=4,286 with HF: PMID 39181597) consolidate the evidence across diabetic and non-diabetic populations and across HFpEF/HFrEF/HFmrEF phenotypes.
  • Metabolic dysfunction-associated steatohepatitis (MASH) with F2/F3 fibrosis β€” FDA-approved indication (August 15, 2025) based on the Phase 3 ESSENCE trial (PMID 40305708, Sanyal AJ, Newsome PN et al., NEJM 2025;392:2089-2099, NCT04822181). In n=800 biopsy-proven MASH patients with F2/F3 fibrosis, semaglutide 2.4 mg weekly achieved 62.9% MASH resolution without worsening fibrosis (vs 34.3% placebo) and 36.8% fibrosis improvement without worsening steatohepatitis (vs 22.4% placebo) at 72 weeks; both primary endpoints met. Semaglutide became the second FDA-approved MASH therapy after resmetirom. Trial design reference: PMID 39412509. Important cirrhosis caveat: The Loomba 2023 Phase 2 trial in MASH-related compensated cirrhosis (F4) did NOT meet its primary endpoint on fibrosis improvement (PMID 36934740) β€” the ESSENCE approval is for F2/F3 only; cirrhosis biology appears less reversible with GLP-1 therapy at this dose/duration.

Protocols Using This Peptide

Ageless Peps Products

Semaglutide is an FDA-approved prescription medication (Ozempic/Wegovy/Rybelsus) manufactured by Novo Nordisk. It is NOT sold by Ageless Peps. No Ageless Peps products contain semaglutide.

For nutraceutical products that support endogenous GLP-1 pathways (NOT GLP-1 receptor agonist drugs), see GLP-1 (Native)#BrainIQ Products Supporting GLP-1 Pathways.

Dosing Reference

Research Dosing Ranges (from literature)

Route Dose Range Frequency Duration Source
SubQ (weight management) 0.25 mg escalating to 2.4 mg Once weekly 68 weeks (STEP 1) PMID 33567185
SubQ (T2D) 0.25 mg escalating to 0.5-1.0 mg (up to 2 mg) Once weekly Ongoing PMID 27633186
SubQ (CV risk reduction) 2.4 mg Once weekly Mean 39.8 months PMID 37952131
Oral (T2D) 3-14 mg Once daily Ongoing Rybelsus prescribing information
Oral (obesity) 50 mg Once daily 68 weeks PMID 37385278

Titration Schedule (Wegovy β€” Weight Management)

Weeks Dose Purpose
1-4 0.25 mg/week GI tolerability initiation
5-8 0.5 mg/week Dose escalation
9-12 1.0 mg/week Dose escalation
13-16 1.7 mg/week Dose escalation
17+ 2.4 mg/week Maintenance dose (standard)

Wegovy HD 7.2 mg Dosing (Higher-Dose Regimen)

FDA approval: March 19, 2026, for adults with obesity who have tolerated the 2.4 mg dosage for β‰₯4 weeks and require additional weight reduction. Approved under the Commissioner's National Priority Voucher Program β€” the fourth NPV-approved product; 54-day review. Full regulatory details: REG-FDA-Wegovy-HD-2026 – Wegovy 7.2 mg National Priority Voucher Approval.

EMA CHMP positive opinion: December 12, 2025. European Commission final authorization decision expected early 2026 β€” nearly parallel US/EU approval timeline. Full EU regulatory context: REG-EMA-Wegovy-7-2mg-CHMP-Opinion-2025 – CHMP Positive Opinion.

Trial basis β€” STEP UP (PMID 40961952, Wharton S et al., Lancet Diabetes Endocrinol 2025;13(11):949-963, NCT05646706). Phase 3b, randomized, double-blind, placebo-controlled, 5:1:1 allocation. n=1,407 adults BMI β‰₯30 without T2D across 95 sites in 11 countries. At 72 weeks:

  • Semaglutide 7.2 mg: βˆ’18.7% mean body weight
  • Semaglutide 2.4 mg: βˆ’15.6%
  • Placebo: βˆ’3.9%
  • β‰₯25% weight loss: 127.4Γ— more likely with 7.2 mg vs placebo

Trial basis β€” STEP UP T2D (PMID 40961953, Lingvay I et al., Lancet Diabetes Endocrinol 2025;13(11):935-948, NCT05649137). n=512 adults BMI β‰₯27 + T2D. At 72 weeks:

  • Semaglutide 7.2 mg: βˆ’13.2% body weight (vs βˆ’3.9% placebo)
  • HbA1c reduction 1.5% greater with 7.2 mg
  • Waist circumference βˆ’6.5 cm greater reduction

Note on T2D population: Weight-loss magnitude is lower in T2D (βˆ’13.2%) than non-T2D (βˆ’18.7%) β€” consistent with the STEP 1/STEP 2 pattern. FDA Wegovy 7.2 mg approval is for obesity indication only; T2D label extension at 7.2 mg would require a separate regulatory filing.

Efficacy at 72 weeks (STEP UP):

  • Semaglutide 7.2 mg: ~20.7% mean body weight reduction (versus βˆ’15.8% at 2.4 mg and placebo-level reduction at placebo)
  • 31.2% of 7.2 mg-treated participants achieved β‰₯25% body weight loss β€” a clinically meaningful new benchmark

Titration pathway:

  • Patients must complete standard Wegovy titration to 2.4 mg and tolerate for β‰₯4 weeks
  • Escalate from 2.4 mg to 7.2 mg per FDA label β€” specific transition schedule to be verified against updated FDA Prescribing Information [NEEDS MD CONFIRMATION]
  • Do not jump to 7.2 mg without prior tolerance of 2.4 mg

Adverse events at higher dose:

  • Class-consistent profile: nausea, diarrhea, vomiting, constipation remain dominant
  • Incidence of GI adverse events at 7.2 mg is numerically higher but not proportionally worse than 2.4 mg in STEP UP
  • Dysesthesia signal (verified STEP UP data): Dysesthesia reported in 22.9% of 7.2 mg participants vs 0.5% of placebo participants in STEP UP (non-T2D) and 18.9% (7.2 mg) vs 4.9% (placebo) in STEP UP T2D. This is the defining new AE of the higher-dose regimen and a new label feature. Clinicians should counsel patients explicitly about altered skin sensation (tingling, burning, numbness), document baseline neurologic exam before escalation to 7.2 mg, and plan dose reduction or discontinuation if dysesthesia is severe or persistent. Rate is lower in T2D population vs non-T2D (mechanism unclear).
  • No new signal for pancreatitis, thyroid C-cell concern at higher dose
  • Gallbladder events remain a consideration given rapid weight loss
  • For the NAION signal: see Adverse Events section below β€” EMA NAION labeling is relevant across all semaglutide doses, not specific to 7.2 mg

Clinical positioning β€” when to use 7.2 mg vs 2.4 mg:

  • First-line remains 2.4 mg per FDA label β€” Wegovy HD is for patients who have tolerated 2.4 mg and require additional weight reduction.
  • Consider 7.2 mg for:
    • Patients at 2.4 mg for β‰₯4 weeks who have not reached their weight-loss goal
    • Patients who achieved partial response but plateaued
    • Patients for whom switch to tirzepatide is not feasible (insurance, tolerability, patient preference)
  • Consider remaining at 2.4 mg for:
    • Patients whose response at 2.4 mg is adequate
    • Patients with tenuous GI tolerability at 2.4 mg
    • Pre-procedural or pre-surgical populations where minimizing peri-procedural GI symptoms is a priority
  • Semaglutide 7.2 mg appears to narrow the weight-loss gap with tirzepatide on cross-trial comparison (20.7% in STEP UP vs. 22.5% in SURMOUNT-1, PMID 40353578), but no head-to-head RCT of 7.2 mg semaglutide vs. 15 mg tirzepatide exists. Direct comparisons remain unavailable. Clinicians should avoid inferring clinical equivalence from cross-trial data alone.

Cycling

Semaglutide is intended for chronic, continuous use rather than cycling. Discontinuation leads to significant weight regain β€” the STEP 5 extension study (PMID 36216945) supports continued therapy for sustained weight maintenance. If discontinuation is necessary, gradual down-titration is recommended to minimize rebound effects.

Withdrawal and Weight Regain β€” The Chronic-Therapy Evidence Base

Two pivotal trials establish that continued semaglutide therapy is required to sustain weight loss and cardiometabolic benefits:

  1. STEP 4 (Rubino DM et al., JAMA 2021;325(14):1414-1425; PMID 33755728) β€” Randomized withdrawal design: after a 20-week open-label run-in with semaglutide 2.4 mg, participants were randomized to continue vs switch to placebo for 48 weeks. Continuing patients experienced an additional βˆ’7.9% weight loss; switching patients had +6.9% weight regain β€” patients who switched regained approximately two-thirds of their run-in weight loss. Cardiometabolic improvements reversed in parallel.

  2. STEP 1 Extension (Wilding JPH et al., Diabetes Obes Metab 2022;24(8):1553-1564; PMID 35441470) β€” 1-year off-treatment follow-up of STEP 1 participants. Participants who had received semaglutide regained approximately two-thirds of their prior weight loss within 52 weeks off treatment; cardiometabolic variables followed parallel reversal patterns.

Both trials converge on the same clinical bottom line: Obesity is a chronic relapsing disease, and weight-management therapy should be framed as indefinite treatment, not a time-limited course. Informed consent at initiation must explicitly address this expectation.

Long-term Durability with Continued Therapy β€” The Counterpoint

While withdrawal produces regain, sustained therapy produces sustained weight loss over years. The SELECT 4-year long-term weight-loss analysis (PMID 38740993, Ryan DH et al., Nat Med 2024;30(7):2049-2057) demonstrates:

  • Mean weight loss of βˆ’10.2% maintained at 208 weeks (4 years) in the full SELECT cohort
  • Waist circumference βˆ’7.7 cm; waist-to-height ratio βˆ’6.9%
  • BMI category shift: Over 2 years, >50% of semaglutide-treated adults moved down β‰₯1 BMI category (vs 16% on placebo); 12% reached a healthy BMI (≀25 kg/mΒ²) vs 1% on placebo
  • Fewer serious adverse events with semaglutide over 4-year follow-up
  • CV benefit from SELECT (20% MACE reduction) occurred independently of baseline adiposity and weight-loss magnitude β€” suggesting direct anti-inflammatory, endothelial, and metabolic mechanisms beyond pure weight loss

The combined message from withdrawal trials (STEP 4, STEP 1 Extension) and long-term extension (SELECT 4-year) is clear: chronic therapy is required; weight and cardiometabolic benefits are sustained with continued therapy.

Emerging Indications (Non-Label)

  • Alcohol use disorder (AUD): Phase 2 RCT (Hendershot CS et al., JAMA Psychiatry 2025;82(4):395-405, PMID 39937469) in n=48 non-treatment-seeking adults with AUD: 9-week semaglutide 0.25β†’0.5β†’1.0 mg reduced grams of alcohol consumed in a laboratory task (Ξ² βˆ’0.48, P=0.01), drinks per drinking day (Ξ² βˆ’0.41, P=0.04), and weekly alcohol craving (Ξ² βˆ’0.39, P=0.01). Findings support potential therapeutic role in AUD; larger adequately-powered trials are underway. Cross-references class-level Bezin (PMID-39844933 – Bezin GLP1 Suicide Attempt Case-Time-Control eClinicalMedicine) and psychiatric-effects SR (PMID-41126551 – Psychiatric Effects GLP1 Systematic Review).

  • Tobacco use disorder (TUD) β€” observational signal: Wang W et al. (Ann Intern Med 2024;177(8):1016-1027, PMID 39074369) target trial emulation using real-world EHR data found semaglutide associated with lower risks of TUD-related health care measures vs other antidiabetes medications (including other GLP-1 RAs), primarily within 30 days of prescription. Hypothesis-generating, not confirmatory. Complementary Phase 2 trial protocol: PMID 40554081 (Yammine, Contemp Clin Trials 2025;155:107989) β€” n=177 smokers with overweight/obesity, 28-week design testing post-cessation weight gain + exploratory abstinence outcomes.

  • Polycystic ovary syndrome (PCOS) with metformin combination: Chen H et al. (Reprod Biol Endocrinol 2025;23(1):108, PMID 40713699) open-label RCT (n=100, 80% completed) β€” combined metformin + semaglutide produced greater weight loss (6.09 kg vs 2.25 kg), greater testosterone reduction, and higher natural pregnancy rate (35% vs 15%) vs metformin alone at 16+ weeks. Hypothesis-generating small-trial signal; off-label use only, with careful counseling around GLP-1 RA pregnancy-discontinuation guidance.

Investigational (Non-Label)

  • Alzheimer's disease (AD) β€” NULL finding on clinical progression: The evoke and evoke+ Phase 3 program (PMID 39780249 design; DOI 10.1016/S0140-6736(26)00459-9 primary results) enrolled n=3,808 adults with early-stage biomarker-confirmed AD (MCI or mild dementia) at 108 sites, randomized to oral semaglutide 14 mg flex-dose vs placebo for 104 weeks. Primary endpoint (CDR-SB change) was not met β€” semaglutide did not slow clinical progression. hsCRP was reduced (ETR 0.76 / 0.71 across trials) but this did not translate to clinical cognitive benefit. The 1-year extension was discontinued. This is an important null finding: AD is not an evidence-supported indication for semaglutide despite earlier observational and preclinical signals. Does not exclude benefit in other cognitive contexts (e.g., diabetic or vascular cognitive impairment).

Regulatory Expansion Timeline + US/EU Divergence

Regulatory milestone timeline:

Date Milestone Reference
June 2021 FDA initial Wegovy approval (adult obesity) β€”
December 2022 FDA adolescent β‰₯12 years indication STEP TEENS
March 8, 2024 FDA MACE-reduction indication (adults with CVD + overweight/obesity) REG-FDA-Wegovy-MACE-2024 – Cardiovascular Risk Reduction Approval
August 2025 FDA MASH indication (F2/F3 fibrosis); oral Wegovy 25 mg approved ESSENCE; OASIS 4
December 12, 2025 EMA CHMP positive opinion for Wegovy 7.2 mg REG-EMA-Wegovy-7-2mg-CHMP-Opinion-2025 – CHMP Positive Opinion
March 19, 2026 FDA Wegovy 7.2 mg approval via National Priority Voucher Program REG-FDA-Wegovy-HD-2026 – Wegovy 7.2 mg National Priority Voucher Approval; STEP UP

The regulatory expansion over five years has moved semaglutide from a narrow weight-management indication to a multi-system chronic-disease-modification agent covering cardiovascular prevention, hepatic steatohepatitis, and obesity across dose ranges. Current authoritative labels: REG-FDA-Wegovy-Label-2025-2026 – Current FDA Prescribing Information (US) and REG-EMA-Wegovy-SmPC-2026 – EU Summary of Product Characteristics (EU).

US vs EU labeling divergences (as of April 2026):

Topic FDA label EMA SmPC
NAION warning NOT included Included as "very rare" (PRAC June 2025)
MACE indication Added March 8, 2024 Approved (parallel timing)
Wegovy 7.2 mg Approved March 19, 2026 (NPV) CHMP positive opinion Dec 12, 2025; EC final decision early 2026
MASH indication Approved August 2025 EU status pending verification
Suicidal ideation warning Removed 2025 Removed 2024-2025

Practitioners with international patients should be aware of these divergences. The NAION divergence is the most clinically material β€” regardless of FDA label status, clinicians should counsel patients on the emerging signal, particularly in those with known ophthalmic risk factors.

Contraindications & Safety

  • BLACK BOX WARNING: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) β€” thyroid C-cell tumor risk observed in rodent models
  • Contraindications: Known hypersensitivity to semaglutide; history of or active pancreatitis (relative); severe gastroparesis
  • Common side effects: Nausea (20-44%), vomiting (10-25%), diarrhea (15-30%), constipation (10-24%) β€” typically dose-dependent, most prevalent during escalation phase, and self-limiting with continued therapy. Slow titration significantly improves GI tolerability (PMID 38787986)
  • Less common: Cholelithiasis/cholecystitis (1-3%), injection site reactions, increased heart rate (1-4 bpm mean increase), fatigue, headache
  • Rare: Acute pancreatitis, acute kidney injury (secondary to dehydration from GI effects), diabetic retinopathy complications (in patients with pre-existing retinopathy and rapid glycemic improvement)
  • Pancreatitis evidence update (Wen 2025 systematic review): The largest contemporary meta-analysis of GLP-1 RA RCTs (62 trials, n=66,232) reports a pooled RR of 1.44 (95% CI 1.09–1.89, P=0.009) for acute pancreatitis β€” a statistically significant but modest relative increase. The signal becomes non-significant when stratified by background medication, and absolute event rates remain low (<1-2% per year). Authors frame the effect as "slightly increased risk, likely minimal" given zero-event-trial exclusions and methodological caveats (PMID 40988099). Clinical action: Maintain standard monitoring β€” history of pancreatitis remains a relative contraindication; discontinue if acute pancreatitis suspected. The Wen data supports continued vigilance rather than either alarmism or clean reassurance.
  • NAION (non-arteritic anterior ischemic optic neuropathy): Multiple converging lines of evidence support a semaglutide-NAION association:
    • Single-center cohort (Hathaway JT et al., JAMA Ophthalmol 2024;142:732-739, PMID 38958939): HR 4.28 (95% CI 1.62–11.29) in T2D patients; HR 7.64 (95% CI 2.21–26.36) in overweight/obese patients for semaglutide prescription
    • Danish nationwide cohort of 424,152 T2D patients (Int J Retina Vitreous 2024, PMID: 39696569): HR 2.19 (95% CI 1.54–3.12) at 5 years
    • 180-country pharmacovigilance analysis (Lakhani M et al., Am J Ophthalmol 2025, PMID: 40383360): FAERS ROR 11.12 (95% CI 8.15–15.16); VigiBase ROR 68.58 (95% CI 16.75–280.67). Same analysis found no significant NAION association for tirzepatide at the same threshold β€” indicating a class-differentiated signal specific to semaglutide.
  • Regulatory divergence on NAION labeling (as of April 2026): The European Medicines Agency required updated NAION warning labels on semaglutide products in August 2024; the EMA PRAC formally classified NAION as a "very rare" side effect of semaglutide (up to 1 in 10,000 patients) in June 2025, with risk estimate of approximately one additional case per 10,000 person-years of treatment (~two-fold increase vs non-users). Full regulatory reference: REG-EMA-PRAC-Semaglutide-NAION-2025 – EMA NAION Very Rare. The US FDA has not updated labels as of April 2026. Clinicians should consider NAION risk in informed consent regardless of US label status, particularly in patients with ophthalmic risk factors (crowded optic disc, history of NAION in fellow eye, hypertension, sleep apnea, dyslipidemia).
  • Drug interactions: Oral medications with narrow therapeutic index may have altered absorption due to gastric emptying delay; monitor warfarin, levothyroxine, oral contraceptives. Caution combining with insulin or sulfonylureas (hypoglycemia risk)
  • Pregnancy/nursing: Contraindicated in pregnancy (Category X based on animal data); discontinue at least 2 months before planned conception due to long half-life. Not recommended during breastfeeding. Human pregnancy-exposure data update (Parker 2025, PMID 40329607): Pooled review of unplanned pregnancies from FDA- and EMA-submitted regulatory clinical trials across GLP-1 RAs (semaglutide, liraglutide, dulaglutide, others). Incidence of congenital abnormalities appears relatively low in this pooled dataset, but sample size is limited and evidence in planned pregnancies is lacking. Standard guidance unchanged: discontinue upon pregnancy awareness; counsel reproductive-age patients on contraception; plan β‰₯2-month washout before planned conception. Authors call for prospective pregnancy registries.
  • Special populations: No dose adjustment for mild-moderate renal/hepatic impairment; limited data in severe renal impairment.
  • Adolescent prescribing (ages β‰₯12 years): Wegovy is FDA-approved for adolescents β‰₯12 years with obesity based on STEP TEENS data (PMID 36322838). Dosing mirrors adult titration (0.25 mg β†’ 2.4 mg weekly SC over 17 weeks). Use within a structured lifestyle-intervention framework and, where available, pediatric obesity-medicine specialist oversight. Counsel adolescents and family on GI tolerability, adherence, contraception considerations in post-menarcheal females, and the chronic-therapy framing. Continued surveillance of long-term developmental, reproductive, and psychosocial outcomes is ongoing.

Cancer Considerations

GLP-1RA Thyroid Cancer Risk: Meta-analysis of 64 RCTs shows thyroid cancer OR 1.52 (PMID-38018310). Real-world data confirms MTC signal at 1-3 years of use (PMID-36356111). The black box warning (MTC/MEN2 history) is evidence-based. However, the definitive 2026 meta-analysis of 48 RCTs (94,245 patients) concludes GLP-1RAs have "little or no effect" on thyroid, pancreatic, breast, or kidney cancers overall (PMID-41359966). Rodent C-cell effects are species-specific and do not translate to primates (PMID-20203154). Action: Screen for MTC/MEN2 history before prescribing. Monitor calcitonin if clinically indicated.

Synergistic Combinations

  • MOTS-C + Semaglutide β€” AMPK activation (MOTS-C) synergizes with GLP-1R signaling for enhanced metabolic improvement; complementary mechanisms for metabolic syndrome
  • 5-Amino-1MQ + Semaglutide β€” NNMT inhibition may enhance adipocyte energy expenditure alongside GLP-1-mediated appetite suppression
  • AOD-9604 + Semaglutide β€” Targeted lipolytic fragment may complement GLP-1-mediated central appetite suppression
  • CagriSema (Cagrilintide + Semaglutide) β€” Amylin analog + GLP-1RA combination; dual receptor approach under investigation (Phase III); superior weight loss versus semaglutide alone
  • Tirzepatide β€” Alternative dual GIP/GLP-1 agonist (not a combination partner, but key comparator showing potentially greater weight loss)

Related Research

PMID Title Year Study Type
PMID-27633186 – SUSTAIN 6 Cardiovascular Outcomes Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes 2016 RCT
PMID-33320179 – Semaglutide Mechanism and Pharmacology Semaglutide: Mechanism of Action, Pharmacology, and Clinical Evidence 2021 Review
PMID-33567185 – Once-Weekly Semaglutide in Adults with Overweight or Obesity Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) 2021 RCT
PMID-33625476 – STEP 3 Semaglutide Intensive Behavioral Therapy Effect of Semaglutide With Intensive Behavioral Therapy (STEP 3) 2021 RCT
PMID-33667417 – STEP 2 Semaglutide in T2D Obesity Semaglutide 2.4 mg for Weight Management in Overweight/Obesity with T2D (STEP 2) 2021 RCT
PMID-34942372 – Semaglutide for the treatment of obesity. Semaglutide for the Treatment of Obesity 2023 Narrative Review
PMID-35015037 – STEP 8 Semaglutide vs Liraglutide Semaglutide vs Liraglutide for Weight Management (STEP 8) 2022 RCT
PMID-36216945 – STEP 5 Semaglutide Long-Term Weight Management Two-Year Effects of Semaglutide on Weight Management (STEP 5) 2022 RCT
PMID-36322838 – STEP TEENS Semaglutide Adolescents Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS) 2022 RCT
PMID-36578889 – Efficacy and Safety of Semaglutide for Weight Loss in Obesit Efficacy and Safety of Semaglutide for Weight Loss: Systematic Review and Meta-Analysis 2022 Meta-analysis
PMID-37385278 – OASIS 1 Oral Semaglutide for Obesity Oral Semaglutide 50 mg for Obesity (OASIS 1) 2023 RCT
PMID-37735340 – Semaglutide Real-World Effectiveness Real-World Effectiveness of Semaglutide for Weight Management 2023 Observational
PMID-37952131 – SELECT Cardiovascular Outcomes Trial Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) 2023 RCT
PMID-38787986 – Semaglutide GI Safety and Tolerability Gastrointestinal Safety and Tolerability of Semaglutide: Meta-Analysis 2024 Meta-analysis
PMID-39476339 – Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis 2024 RCT
PMID-40162642 – SOUL Oral Semaglutide CV Outcomes Oral Semaglutide and Cardiovascular Outcomes in High-Risk T2D (SOUL) 2025 RCT
PMID-40169145 – STRIDE Semaglutide PAD Semaglutide and Walking Capacity in PAD + T2D (STRIDE) 2025 RCT
REG-FDA-Wegovy-HD-2026 – Wegovy 7.2 mg National Priority Voucher Approval Wegovy HD 7.2 mg FDA Approval 2026 Regulatory
REG-EMA-PRAC-Semaglutide-NAION-2025 – EMA NAION Very Rare EMA PRAC NAION "Very Rare" Classification 2025 Regulatory
PMID-39696569 – Danish Norwegian NAION Cohort Danish/Norwegian Nationwide NAION Cohort (n=424,152) 2024 Cohort
PMID-40383360 – Lakhani 180 Countries GLP-1 Ocular Events 180-Country Pharmacovigilance of GLP-1 Ocular Events (Lakhani) 2025 Pharmacovigilance
PMID-40353578 – SURMOUNT-5 Tirzepatide vs Semaglutide SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head 2025 RCT
PMID-20203154 – GLP-1RA Rodent Thyroid C-Cell Activation GLP-1RA Rodent Thyroid C-Cell Activation (Mechanism) 2010 Preclinical
PMID-36356111 – GLP-1RA and Risk of Thyroid Cancer GLP-1RA and Risk of Thyroid Cancer (Real-World Cohort) 2022 Cohort
PMID-38018310 – GLP-1RA Thyroid Cancer Risk Meta-Analysis of RCTs GLP-1RA Thyroid Cancer Risk: Meta-Analysis of 64 RCTs 2023 Meta-Analysis
PMID-41359966 – GLP-1RA Cancer Risk Systematic Review 94245 Patients GLP-1RA Cancer Risk Systematic Review (94,245 patients) 2026 Systematic Review
CONF-2025-ACC-SOUL-LateBreaker ACC.25 Late-Breaker: SOUL (McGuire) β€” conference presentation 2025 Conference abstract
CONF-2025-ACC-STRIDE-LateBreaker ACC.25 Late-Breaker: STRIDE (Bonaca) β€” conference presentation 2025 Conference abstract
CONF-2025-EASD-Vilsboll-NAION EASD 2025 Vienna: VilsbΓΈll NAION pooled-trial incidence (late-breaker) 2025 Conference abstract
PMID-41021211 – Cheng GLP1 Ophthalmic Pharmacovigilance FAERS VigiBase Cheng Multi-Database Pharmacovigilance of GLP-1 Ophthalmic Risks (FAERS + VigiBase) 2026 Pharmacovigilance
PMID-39844933 – Bezin GLP1 Suicide Attempt Case-Time-Control eClinicalMedicine Bezin Nationwide French Case-Time-Control: GLP-1 RA + Suicide/Attempt 2024 Case-time-control
PMID-33755728 – STEP 4 Rubino Weight Maintenance Withdrawal STEP 4: Continued Sem 2.4 mg vs Placebo on Weight-Loss Maintenance 2021 RCT (withdrawal)
PMID-35441470 – STEP 1 Extension Wilding Weight Regain After Withdrawal STEP 1 Extension: Weight Regain and Cardiometabolic Effects After Withdrawal 2022 RCT extension
PMID-37622681 – STEP-HFpEF Kosiborod Semaglutide HFpEF Obesity STEP-HFpEF: Semaglutide in HFpEF + Obesity (no T2D) 2023 Phase 3 RCT
PMID-38587233 – STEP-HFpEF DM Kosiborod Semaglutide HFpEF T2D STEP-HFpEF DM: Semaglutide in HFpEF + Obesity + T2D 2024 Phase 3 RCT
PMID-38599221 – Butler Pooled STEP-HFpEF Lancet 2024 Butler Pooled STEP-HFpEF + STEP-HFpEF DM 2024 Pooled analysis
PMID-39222642 – Kosiborod 4-Trial Pooled HF Lancet 2024 Kosiborod 4-Trial Pooled HF Analysis (SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM) 2024 Pooled analysis
PMID-39181597 – SELECT HF Prespecified Subgroup Lancet 2024 SELECT Prespecified HF Subgroup (HFpEF + HFrEF + Unclassified) 2024 Prespecified subgroup
PMID-38740993 – SELECT 4-Year Long-term Weight Loss Ryan SELECT 4-Year: Long-term Weight Loss Effects of Semaglutide 2024 Phase 3 extension
PMID-39937469 – Hendershot Semaglutide Alcohol Use Disorder RCT Hendershot: Semaglutide in Alcohol Use Disorder (Phase 2 RCT) 2025 Phase 2 RCT
PMID-39780249 – EVOKE EVOKE+ Design Oral Semaglutide Alzheimer evoke and evoke+ Phase 3 Design (oral sem in early AD) 2025 Phase 3 design
DOI-10-1016-S0140-6736-26-00459-9 – EVOKE Primary Results Johannsen Lancet 2026 EVOKE / EVOKE+ Phase 3 Primary Results (null CDR-SB) 2026 Phase 3 RCT
PMID-37385279 – PIONEER PLUS Aroda Oral Semaglutide 25mg 50mg T2D PIONEER PLUS: Oral Sem 25/50 mg vs 14 mg in T2D 2023 Phase 3b RCT
PMID-40934115 – OASIS 4 Wharton Oral Semaglutide 25mg Obesity OASIS 4: Oral Sem 25 mg in Overweight/Obesity 2025 Phase 3 RCT
PMID-40305708 – ESSENCE Sanyal Newsome Semaglutide MASH Phase 3 ESSENCE: Semaglutide Phase 3 in MASH (FDA-approved indication Aug 2025) 2025 Phase 3 RCT
PMID-39412509 – ESSENCE Design Baseline Characteristics ESSENCE: Baseline Characteristics and Design 2024 Trial design
PMID-36934740 – Loomba Semaglutide MASH Cirrhosis Phase 2 Loomba: Semaglutide in MASH-related Cirrhosis (negative primary) 2023 Phase 2 RCT
PMID-40961952 – STEP UP Wharton Semaglutide 7.2 mg Obesity STEP UP: Semaglutide 7.2 mg in Obesity (n=1,407; βˆ’18.7% at 72 wk) 2025 Phase 3b RCT
PMID-40961953 – STEP UP T2D Lingvay Semaglutide 7.2 mg STEP UP T2D: Semaglutide 7.2 mg in Obesity + T2D (n=512; βˆ’13.2%, HbA1c βˆ’1.5%) 2025 Phase 3b RCT
REG-FDA-Wegovy-Label-2025-2026 – Current FDA Prescribing Information Current FDA Wegovy Prescribing Information (NDA 215256) 2025-2026 Regulatory
REG-FDA-Wegovy-MACE-2024 – Cardiovascular Risk Reduction Approval FDA MACE-Reduction Indication Approval (March 8, 2024) 2024 Regulatory
REG-EMA-Wegovy-SmPC-2026 – EU Summary of Product Characteristics EMA Wegovy SmPC (Current EU Label) 2026 Regulatory
REG-EMA-Wegovy-7-2mg-CHMP-Opinion-2025 – CHMP Positive Opinion EMA CHMP Positive Opinion for Wegovy 7.2 mg (Dec 12, 2025) 2025 Regulatory
PMID-40988099 – Wen Pancreatitis Pancreatic Cancer GLP-1 Systematic Review Wen: GLP-1 RA Pancreatitis Risk Meta-Analysis (62 RCTs, n=66,232; RR 1.44) 2025 SR/Meta-analysis
PMID-39074369 – Wang Semaglutide Tobacco Use Disorder Ann Intern Med Wang: Semaglutide + TUD in T2D (target trial emulation) 2024 Observational
PMID-40554081 – Yammine Semaglutide Smoking Cessation Protocol Yammine: Semaglutide for Post-Cessation Weight Gain (Phase 2 protocol) 2025 Phase 2 protocol
PMID-40329607 – Parker GLP-1 Pregnancy Regulatory Safety Data Parker: GLP-1 RA Use in Pregnancy β€” Regulatory Safety Data 2025 Regulatory review
PMID-40713699 – Chen Metformin Semaglutide PCOS RCT Chen: Metformin + Semaglutide in PCOS (open-label RCT, n=100) 2025 RCT (open-label)

References

  • PMID 27633186 β€” Marso SP et al. SUSTAIN 6. N Engl J Med. 2016.
  • PMID 33320179 β€” Mechanism and pharmacology review.
  • PMID 33567185 β€” Wilding JPH et al. STEP 1. N Engl J Med. 2021.
  • PMID 33625476 β€” Wadden TA et al. STEP 3. JAMA. 2021.
  • PMID 33667417 β€” Davies M et al. STEP 2. Lancet. 2021.
  • PMID 34942372 β€” Chao AM et al. Trends Cardiovasc Med. 2023.
  • PMID 35015037 β€” Rubino DM et al. STEP 8. JAMA. 2022.
  • PMID 36216945 β€” Garvey WT et al. STEP 5. Nat Med. 2022.
  • PMID 36322838 β€” Weghuber D et al. STEP TEENS. N Engl J Med. 2022.
  • PMID 36578889 β€” Tan HC et al. Meta-analysis. J ASEAN Fed Endocr Soc. 2022.
  • PMID 37385278 β€” Knop FK et al. OASIS 1. Lancet. 2023.
  • PMID 37735340 β€” Real-world semaglutide data. 2023.
  • PMID 37952131 β€” Lincoff AM et al. SELECT. N Engl J Med. 2023.
  • PMID 38787986 β€” GI safety meta-analysis. 2024.
  • PMID 39476339 β€” Bliddal H et al. N Engl J Med. 2024.
  • PMID 40162642 β€” McGuire DK et al. SOUL. N Engl J Med. 2025;392(20):2001-2012.
  • PMID 40169145 β€” Bonaca MP et al. STRIDE. Lancet. 2025;405(10489):1580-1593.
  • FDA (March 19, 2026). Wegovy HD (semaglutide 7.2 mg) approval β€” National Priority Voucher.
  • EMA PRAC (June 2025). NAION classified as very rare side effect of semaglutide.
  • PMID 39696569 β€” Danish/Norwegian Nationwide NAION Cohort (n=424,152). Int J Retina Vitreous. 2024.
  • PMID 40383360 β€” Lakhani M et al. 180-Country Pharmacovigilance of GLP-1 Ocular Events. Am J Ophthalmol. 2025.
  • PMID 40353578 β€” SURMOUNT-5 Tirzepatide vs Semaglutide Head-to-Head. 2025.
  • PMID 20203154 β€” GLP-1RA Rodent Thyroid C-Cell Activation (mechanism). 2010.
  • PMID 36356111 β€” GLP-1RA and Risk of Thyroid Cancer (real-world cohort). 2022.
  • PMID 38018310 β€” GLP-1RA Thyroid Cancer Risk: Meta-Analysis of 64 RCTs. 2023.
  • PMID 41359966 β€” GLP-1RA Cancer Risk Systematic Review (94,245 patients). 2026.
  • PMID 40961952 β€” STEP UP / Wegovy HD trial publication. Lancet Diabetes Endocrinol. 2025 β€” NOTE: no dedicated research note in vault as of audit; referenced in prose and Wegovy HD regulatory note.
  • ACC.25 Late-Breaking Clinical Trial, March 29, 2025 β€” SOUL (oral semaglutide CV outcomes, McGuire DK presenter). Conference context: CONF-2025-ACC-SOUL-LateBreaker.
  • ACC.25 Late-Breaking Clinical Trial, March 29, 2025 β€” STRIDE (semaglutide + PAD, Bonaca MP presenter). Conference context: CONF-2025-ACC-STRIDE-LateBreaker.
  • EASD 2025 Late-Breaking Abstract LBA-25-3912-EASD, September 2025, Vienna β€” VilsbΓΈll NAION pooled-trial incidence analysis. Conference context: CONF-2025-EASD-Vilsboll-NAION.
  • PMID 41021211 β€” Cheng X et al. Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks. J Endocrinol Invest. 2026;49(2):425-433.
  • PMID 39844933 β€” Bezin J et al. Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. EClinicalMedicine. 2024;80:103029.
  • PMID 33755728 β€” Rubino D et al. STEP 4: Effect of Continued Weekly Semaglutide vs Placebo on Weight-Loss Maintenance. JAMA. 2021;325(14):1414-1425.
  • PMID 35441470 β€” Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
  • PMID 37622681 β€” Kosiborod MN et al. Semaglutide in Patients with HFpEF and Obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084.
  • PMID 38587233 β€” Kosiborod MN et al. Semaglutide in Patients with Obesity-Related HF and T2D (STEP-HFpEF DM). N Engl J Med. 2024;390(15):1394-1407.
  • PMID 38599221 β€” Butler J et al. Semaglutide vs placebo in obesity-related HFpEF: pooled analysis of STEP-HFpEF and STEP-HFpEF DM. Lancet. 2024;403(10437):1635-1648.
  • PMID 39222642 β€” Kosiborod MN et al. Semaglutide vs placebo in HF (HFpEF/HFmrEF): pooled SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM. Lancet. 2024;404(10456):949-961.
  • PMID 39181597 β€” Kosiborod MN, Deanfield J et al. SELECT prespecified HF subgroup. Lancet. 2024;404(10454):773-786.
  • PMID 38740993 β€” Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without DM: SELECT 4-year. Nat Med. 2024;30(7):2049-2057.
  • PMID 39937469 β€” Hendershot CS et al. Once-Weekly Semaglutide in Adults with Alcohol Use Disorder: RCT. JAMA Psychiatry. 2025;82(4):395-405.
  • PMID 39780249 β€” Cummings JL et al. evoke and evoke+ design: Phase 3 studies of semaglutide in early AD. Alzheimers Dement. 2025;21(1):e14303.
  • DOI 10.1016/S0140-6736(26)00459-9 β€” Johannsen P et al. evoke and evoke+ primary results: oral semaglutide in early AD. Lancet. 2026.
  • PMID 37385279 β€” Aroda VR et al. PIONEER PLUS: oral sem 25/50 mg vs 14 mg in T2D. Lancet. 2023;402(10403):693-704.
  • PMID 40934115 β€” Wharton S et al. OASIS 4: Oral Semaglutide 25 mg in Overweight/Obesity. N Engl J Med. 2025;393:1077-1087.
  • PMID 40305708 β€” Sanyal AJ, Newsome PN et al. ESSENCE Phase 3 Trial of Semaglutide in MASH. N Engl J Med. 2025;392:2089-2099.
  • PMID 39412509 β€” Newsome PN et al. ESSENCE baseline characteristics and design. Aliment Pharmacol Ther. 2024;60(11-12):1525-1537.
  • PMID 36934740 β€” Loomba R et al. Semaglutide 2.4 mg in NASH-related cirrhosis: Phase 2. Lancet Gastroenterol Hepatol. 2023;8(6):511-522.
  • PMID 40961952 β€” Wharton S et al. STEP UP: Once-weekly semaglutide 7.2 mg in obesity. Lancet Diabetes Endocrinol. 2025;13(11):949-963.
  • PMID 40961953 β€” Lingvay I et al. STEP UP T2D: Once-weekly semaglutide 7.2 mg in obesity + T2D. Lancet Diabetes Endocrinol. 2025;13(11):935-948.
  • FDA. Wegovy (semaglutide) Prescribing Information β€” NDA 215256, current label. 2025-2026.
  • FDA (March 8, 2024). Wegovy MACE-reduction indication press announcement.
  • EMA. Wegovy Summary of Product Characteristics β€” EPAR page. 2026.
  • EMA CHMP (December 12, 2025). Positive opinion for Wegovy 7.2 mg.
  • PMID 40988099 β€” Wen J et al. GLP-1 RA pancreatitis + pancreatic cancer: systematic review + meta-analysis of 62 RCTs. Endocrinol Diabetes Metab. 2025;8(5):e70113.
  • PMID 39074369 β€” Wang W et al. Association of semaglutide with tobacco use disorder in T2D: target trial emulation. Ann Intern Med. 2024;177(8):1016-1027.
  • PMID 40554081 β€” Yammine L et al. RCT of once-weekly semaglutide for post-smoking-cessation weight gain: protocol. Contemp Clin Trials. 2025;155:107989.
  • PMID 40329607 β€” Parker CH et al. GLP-1 RA use during pregnancy: regulatory clinical trials safety data. Diabetes Obes Metab. 2025;27(8):4102-4108.
  • PMID 40713699 β€” Chen H et al. Metformin + semaglutide in overweight/obese PCOS: RCT. Reprod Biol Endocrinol. 2025;23(1):108.

FDA Disclaimer: Semaglutide (Ozempic, Wegovy, Rybelsus) is an FDA-approved prescription medication. It requires a valid prescription from a licensed healthcare provider. The clinical data presented here is for educational reference only and does not constitute medical advice. Dosing must be individualized by a clinician.

Related

#peptide #metabolic #subq #oral